Comparison
Deep 6 AI vs Triomics
Deep 6 AI and Triomics both built EHR trial matching that reads unstructured notes and reports and sends the matches to site staff.[7],[11],[1],[2] Triomics is an oncology platform that screens the patients on a cancer center's upcoming clinic schedule inside Epic, OncoEMR and iKnowMed.[2],[3] Deep 6 AI, which health systems used across all their trials, has been a Tempus company since March 11, 2025, and Tempus now sells trial matching through TIME and Next Trials.[10],[6],[14],[9] Neither publicly documents calling or texting matched patients or booking their visits. Bond Health finds patients in the EHR and then contacts, pre-screens and schedules them.[15]
Last updated Oct 23, 202616 sources
Partnered with
What is the difference between Deep 6 AI and Triomics?
- Focus. Triomics says it is "built for cancer care's complexity".[1] Deep 6 AI was used enterprise-wide for investigator-initiated, government-funded and sponsored trials.[10]
- When screening runs. Triomics PRISM screens "every upcoming patient on tomorrow's schedule and the week ahead" against the site's active trials, refreshes nightly and re-checks eligibility whenever the chart updates.[2] Deep 6 AI matched patients by mining real-time structured and unstructured EMR data.[7]
- Where matches go. Triomics sends matches as an EHR in-basket message, in the PRISM worklist or by email before clinic starts.[2] In Deep 6 AI, site staff validated each patient's eligibility with evidence in the EMR and tracked recruitment status and referrals there.[11]
- Where each company is now. Tempus, which acquired Deep 6 AI, sells trial matching through TIME, its oncology trial network, and Next Trials, which pre-screens for trials already open at a practice. Deep 6 AI's own website no longer loads.[6],[8],[9],[14] Besides PRISM for trial matching, Triomics offers Symphony for visit preparation and Harmony for data curation.[5]
- Sponsors. Both sell to life sciences companies through the sites that run them. Triomics describes "one AI platform, deployed at the sites, sponsor-ready outputs", and Deep 6 AI let sponsors share AI-matched patient cohorts with site staff.[4],[11]
How do Deep 6 AI, Triomics and Bond compare, capability by capability?
Years in the Deep 6 AI and Triomics columns show each source's date. "Not publicly documented" means we found no public description in the materials we reviewed in October 2026, not that the capability is absent.
| Capability | Deep 6 AI (Tempus) | Triomics | Bond Health |
|---|---|---|---|
| Therapeutic focus | Was used enterprise-wide across a health system's investigator-initiated, government-funded and sponsored trials (2024).[10] | Oncology. "Built for cancer care's complexity" (2026).[1] | Any therapeutic area. Screening is configured from each protocol's own criteria, for drug and device studies alike.[15],[16] |
| EHR identification | Mined real-time structured and unstructured EMR data to match patients to trials (2025).[7] | PRISM screens patients on the upcoming clinic schedule against every active trial, refreshes nightly and re-checks when the chart updates (2026).[2] | LLM-based screening of the site's EHR against each protocol's criteria, returning ranked matches: 10,000+ charts per hour and 90%+ matching accuracy.[15] |
| Unstructured data | NLP over physician notes, lab, radiology and pathology reports, and genomics results (2023).[12] | Reasons across "every note, report and fax" and reads HL7, FHIR, CCDA and XML data plus PDFs, TIFFs and JPEGs (2026).[1],[3] | Reads clinical notes, prescriptions and lab results, and uses imaging data and other unstructured documents, including pathology, radiology and molecular reports.[15],[16] |
| Evidence behind each match | Highlighted the patient data related to each inclusion and exclusion criterion and showed the text where its NLP found each keyword (2024).[13] | Delivers "structured, cited answers" into the cancer center's workflows (2026).[1] | Ranked matches come with the evidence behind each criterion decision and traceability to the chart.[15] |
| Where matches go | Site staff validated eligibility with evidence in the EMR and tracked recruitment status and referrals (2023).[11] | An EHR in-basket message, the PRISM worklist or an email to staff, before clinic starts (2026).[2] | Straight to Bond's voice and SMS agents, which contact the patient, alongside a dashboard for the site team.[15],[16] |
| Patient outreach and scheduling | Automated calls or texts to matched patients, and visit booking: not publicly documented (October 2026). | Not publicly documented (October 2026). The matches go to staff, not to patients.[2] | Voice and SMS agents contact matched patients, starting from what Identify found in the chart, and can pre-screen and book a visit in one conversation, in the patient's language. Bond's site cites a 3x contact rate.[15],[16] |
| Consent | Patient-facing consent support: not publicly documented (October 2026). | Not publicly documented (October 2026). | Plain-language explanations, patient Q&A and staff escalation, with checks on the patient's understanding and an auditable record for the site. The site and PI obtain consent.[15],[16] |
| Support after enrollment | Not publicly documented (October 2026). | Not publicly documented (October 2026). | Visit reminders, transportation booking, symptom and diary collection, side-effect check-ins and flags for participants at risk of dropping out.[16] |
| EHR connections | Integrated with the health system's EMR (2023) and could bring in genomics, cancer registry and CTMS data (2024).[12],[13] | Native integrations with Epic, OncoEMR and iKnowMed, and approved on the Epic App Marketplace (2026). Its PRISM page also lists Cerner.[3],[2] | Epic, Oracle Health (Cerner), MEDITECH, athenahealth, eClinicalWorks, NextGen, Veradigm, OncoEMR and the other major EHRs, via FHIR and HL7 or an aggregator, plus CTMS systems including CRIO, Advarra OnCore, RealTime and Veeva SiteVault. Live in 48 hours, with no integration fee (implementation).[15],[16] |
| Who it serves | Health systems, often through the Clinical Trials Office, and life sciences companies (2024).[10] | Cancer centers, and life sciences companies through the sites that run it (2026).[3],[4] | Any research site, including physician groups and FQHCs, plus site networks, CROs and sponsors.[15] |
| Pricing | No public price list found (October 2026). | No public price list found (October 2026). The website offers a demo.[1] | A volume-based fee per screened patient plus a percentage of the randomization milestone payment for each patient, with no integration fee (pricing).[16] |
Should you choose Deep 6 AI or Triomics?
- Choose Triomics if you are a cancer center on Epic, OncoEMR or iKnowMed and want every scheduled patient checked against your trial portfolio before clinic, with matches in the in-basket. Its Symphony and Harmony products add visit preparation and data curation.[2],[3],[5]
- Choose Tempus, which owns Deep 6 AI, if you run oncology trials and want matching tied to its TIME network or Next Trials pre-screening for trials already open at your practice. Ask Tempus which Deep 6 AI capabilities it still offers, since Deep 6 AI's own website no longer loads.[8],[9],[14]
- Choose Bond if the bottleneck is what happens after the match: someone has to call each patient, pre-screen them, book the visit and walk them through consent. Bond does all of that, in any therapeutic area, from the same EHR screening.[15],[16]
Why do sites choose Bond over Deep 6 AI and Triomics?
48 hours[15]
typical time to go live with full EHR integration, handled by Bond's team with no integration fee
10,000+[15]
charts screened per hour
Up to 3x[15]
faster enrollment than manual recruitment
- One product from chart to booked visit. Bond automates EHR screening, patient outreach, visit booking and consent tracking in one workflow, with "no data silos, no manual handoffs, and complete visibility from first ad click or chart match to a booked visit and signed consent."[15]
- Every ad lead contacted immediately, and followed up until they book. Bond creates and runs Meta and Google ad campaigns for each study. Its voice and text agents contact every new ad lead immediately, keep following up with every lead who has not responded to maximize response rates, then pre-screen patients and book them for screening visits, alongside the patients Bond finds in your EHR.[16]
- Agents that start from the chart. Bond's voice agents skip questions the chart already answers, can explain why the patient was contacted, and transfer live to a coordinator when the site wants that, in the patient's language.[16]
- Every open study at once. Bond screens each patient against every open study at the site, so a patient who screens out of one study can be matched to another.[16]
- Security you can check. Bond is HIPAA compliant and SOC 2 Type I compliant, and its information security management system is certified to ISO/IEC 27001:2022 by Advantage Partners. See security.[16]
How can you test Deep 6 AI, Triomics and Bond on your own data?
Run a pilot on your own records, under a business associate agreement. A demo shows an interface; a pilot shows which tool gets more eligible patients to a screening visit.
- 1
Pick a study with a known answer
Use a closed or mature study where coordinators know who enrolled, who screen-failed and why. For Triomics, it has to be an oncology study.
- 2
Give every vendor the same protocol and patients
Same criteria, same records. Ask for the chart evidence behind every criterion decision, not only a score.
- 3
Count what happens after the match
Track who contacts each matched patient, how fast, how many are reached and how many reach a screening visit. With a matching-only tool, that work is your coordinators' time.
- 4
The vendor evaluation checklist turns these steps into questions, and all recruitment software, one table covers the wider category.
Bring one protocol. We will show how Bond handles its hardest criteria, then how it contacts and books the patients it finds.
How was this comparison made?
Bond wrote this page in October 2026. Triomics facts come from its website, read in October 2026; parts of the site appeared to be mid-update, so check its live pages for changes. Deep 6 AI facts come from Tempus's 2025 Form 10-K, Deep 6 AI and Tempus press releases, Tempus web pages, an archived copy of Deep 6 AI's website and an Ohio State customer abstract. deep6.ai itself did not load in October 2026. Bond's figures and capabilities come from its website and product information Bond provided. We used no private or internal competitive material.
Frequently asked questions
Is Triomics better than Deep 6 AI?
For cancer centers, Triomics is the more specialized tool: it is built for oncology and checks each scheduled patient against every active trial inside Epic, OncoEMR or iKnowMed.[1],[2],[3] Deep 6 AI was built for health systems running one matching tool across all their trials, and it is now part of Tempus.[10],[6] Neither publicly documents contacting matched patients; Bond does, and then books their visits.[15]
Does Triomics contact patients?
Not according to its public materials. PRISM sends matches to staff as an EHR in-basket message, a worklist entry or an email.[2] We found no description of calling or texting patients, booking visits or consent support as of October 2026.
Is Deep 6 AI part of Tempus?
Yes. Tempus's 2025 Form 10-K says it acquired Deep 6 AI, Inc. on March 11, 2025.[6] By January 2026, Deep 6 AI's website said it "is now a Tempus AI company".[14] See Bond vs Tempus (Deep 6 AI) for TIME and Next Trials.
How much do Deep 6 AI and Triomics cost?
Neither publishes a price list as of October 2026. Bond charges a volume-based fee per screened patient plus a percentage of the randomization milestone payment for each patient, with no integration fee (pricing).[16] See what recruitment software costs.
Sources
- 1.Triomics homepage · Triomics, 2026Accessed October 2026. Quotes: "Built for cancer care's complexity"; "Our AI agents reason across every note, report and fax in a patient's record and deliver structured, cited answers … directly into the workflows that run a cancer center."; "Coordinators stop reading charts to rule patients out."
- 2.PRISM: clinical trial matching · Triomics, 2026Accessed October 2026. Quotes: "PRISM screens every upcoming patient on tomorrow's schedule and the week ahead against every active trial in your portfolio, then refreshes the results nightly as each visit approaches."; "Matches arrive as an EHR in-basket message or in the PRISM worklist before clinic starts"; "Matches can surface as in-basket or email notifications when the chart updates"; "PRISM re-evaluates eligibility every time the chart updates"; "Federally funded, investigator-initiated, industry-sponsored. Your full portfolio, no exceptions."; "Native in Epic, Cerner, OncoEMR. Approved on the Epic App Marketplace."
- 3.Triomics for cancer centers · Triomics, 2026Accessed October 2026. Quotes: "HL7, FHIR, CCDAs, XMLs, PDFs, TIFFs, JPEGs."; "Native integrations with Epic, OncoEMR, iKnowMed. Approved on the Epic App Marketplace. Outputs land in in-baskets, worklists, and EHR notes."
- 4.Triomics for life sciences · Triomics, 2026Accessed October 2026. Quotes: "One AI platform, deployed at the sites, sponsor- ready outputs."; "Triomics deployments are governed by site agreements."
- 5.About Triomics · Triomics, 2026Accessed October 2026. Quote: "Today, it powers PRISM for trial matching, Symphony for visit prep, and Harmony for data curation."
- 6.Tempus AI, Inc. Form 10-K for fiscal year ended December 31, 2025 · Tempus AI, Inc. / U.S. Securities and Exchange Commission, 2026Filed February 2026, accessed September 2026. Quote: "On March 11, 2025, the Company acquired all of the issued and outstanding interests of Deep 6 AI, Inc." Revenue: "The Company's Trials product includes TIME clinical trial matching services and other clinical trial services"; "To the extent the contract requires, the Company may also assist in opening the clinical trial site and enrolling the patient in the clinical trial"; "depending on the type of agreement"; "revenue is recognized upon one of the following: delivery of a notification to the physician alerting them to a clinical trial match, or once a patient is enrolled in a trial"; "the customer, which is the clinical trial sponsor". Data connections: "We use a variety of near real-time connections (e.g., HL7, FHIR) and batch data exchanges"; "Our proprietary tools connect to a provider's EHR system, data warehouse, or third-party data provider to pull out relevant structured and unstructured data that the provider has agreed to provide to Tempus"; "In certain circumstances, we cover the actual direct costs associated with the technical integrations needed to create a data connection."
- 7.Tempus Announces Acquisition of Deep 6 AI · Tempus AI, Inc. press release, 2025Press release dated March 11, 2025, read October 23, 2026. Quotes: "today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies" and "Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record (EMR) data".
- 8.Clinical Trial Matching for Oncology | TIME Trial Network · Tempus AI, Inc. (tempus.com), 2026Re-checked on tempus.com October 23, 2026. Quote: trial matching "with a clinical team of experts pre-screening the matched patients and presenting potentially eligible patients with a white-glove service to each site" and, under enhanced patient pre-screening, "Generative AI scans structured and unstructured clinical notes, enhancing identification of patients who may be eligible for trial participation."
- 9.Tempus Next Trials · Tempus AI, Inc. (tempus.com), 2026Read October 23, 2026. Quotes: "AI-enabled platform supports clinical trial pre-screening based on your patients' multimodal, structured and unstructured health information (clinical, imaging and molecular data)"; "Accelerate accrual to trials already open at your practice"; "AI-enhanced workflows are designed to assist site clinicians in identifying, screening and enrolling eligible patients for TIME trials."; "When ready, Next Trials can be expanded to pre-screen patients across additional disease groups beyond oncology."
- 10.Doug Cassidy Appointed President of the Deep 6 AI Precision Research Ecosystem · Deep 6 AI (PR Newswire), 2024Company press release, July 24, 2024. Quote: "Healthcare organizations that become part of the Ecosystem use the company's AI-powered software platform enterprise-wide for investigator-initiated, government-funded, and sponsored trials. Often, the technology is managed centrally (i.e., by the Clinical Trials Office)" and "the launch of our life sciences vertical in 2021".
- 11.Deep 6 AI Expands its Recruitment Acceleration Solution for Life Sciences · Deep 6 AI (PR Newswire), 2023Company press release, December 6, 2023. Quote: "Life sciences companies can share AI-matched patient cohorts with IRB-approved site staff across the Deep 6 AI ecosystem. This allows sites to identify each patient, validate their eligibility with evidence in the EMR, and track their recruitment statuses" and "The site's research team can easily identify eligible patients treated by physicians other than the principal investigator, validate them, and track referrals inside the EMR."
- 12.Texas Tech University Health Sciences Center Partners with Deep 6 AI to Launch an AI Program for Clinical Trials · Deep 6 AI (PR Newswire), 2023Company press release, August 1, 2023. Quote: Deep 6 AI uses natural language processing to search "structured and unstructured EMR data points, such as physician notes, lab reports, outpatient notes, radiology reports, genomics results, and pathology reports" and "By integrating with TTUHSC's EMR, Deep 6 AI's software platform can precision-match patients to trials".
- 13.Integrating AI-Enabled Clinical Trial Matching into Operations · Stillman R, Campbell A, Humphries K, Schweitzer C. The Ohio State University Comprehensive Cancer Center; AACI CRI 2024 abstract, 2024Customer work-in-progress abstract on Deep 6 AI at Ohio State, accessed September 2026. Quote: "a user interface that speeds patient screening by presenting and highlighting patient data related to the inclusion/exclusion criteria across a longitudinal patient record"; "to be able to reference the text in which the NLP identified the keywords to view the keywords in context to confirm the finding"; "Deep 6 AI can incorporate multiple data sources beyond the electronic medical records (EMR), such as genomics, custom databases, cancer registries, CTMS, etc."
- 14.Deep 6 AI homepage (archived) · Deep 6 AI, via the Internet Archive, 2026Internet Archive copy of January 3, 2026. Quotes: "Deep 6 AI has joined Tempus." and "Deep 6 AI is now a Tempus AI company". deep6.ai itself did not load when we checked on October 23, 2026.
- 15.Bond Health: platform overview, FAQ and pricing · Bond Health, 2026
- 16.Bond Health product information · Bond Health, 2026Capabilities, pricing and compliance status described by Bond Health, October 2026.
Related pages
Bond vs Tempus (Deep 6 AI)
Deep 6 AI, TIME and Next Trials, compared with Bond.
ReadDeep 6 AI vs Paradigm Health
Matching software vs a sponsor-funded research network.
ReadRecruitment software compared
The wider category, vendor by vendor.
ReadPricing
No integration fee: a volume-based fee per screened patient plus a percentage of the randomization milestone payment for each patient.
ReadSecurity
How Bond handles PHI, BAAs and audit logging.
ReadOncology recruitment
Where oncology criteria sit in the chart, and how Bond screens for them.
Read